Anzeige
Meldung des Tages: Das Triple-Discovery-Setup, das der Markt noch nicht begriffen hat!!

Vanda Pharmaceuticals News

Aktie
WKN:  A0JJT3 ISIN:  US9216591084 US-Symbol:  VNDA Branche:  Biotechnologie Land:  USA
7,45 €
-0,05 €
-0,67%
12:04:52 Uhr
Depot/Watchlist
Marktkapitalisierung *
348,72 Mio. €
Streubesitz
14,40%
KGV
-14,97
Index-Zuordnung
-

Vanda Pharmaceuticals News

03.03.26 - PR Newswire
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years PR Newswire
26.02.26 - PR Newswire
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference PR Newswire
25.02.26 - PR Newswire
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis PR Newswire
20.02.26 - PR Newswire
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New ...
12.02.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA PR Newswire
11.02.26 - PR Newswire
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire
04.02.26 - PR Newswire
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 PR Newswire
29.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA PR Newswire
22.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA PR Newswire
15.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA PR Newswire
08.01.26 - PR Newswire
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder PR Newswire
30.12.25 - PR Newswire
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion ...
15.12.25 - PR Newswire
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis PR Newswire
11.12.25 - PR Newswire
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference PR Newswire
04.12.25 - PR Newswire
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness PR Newswire
28.11.25 - PR Newswire
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness PR Newswire
17.11.25 - PR Newswire
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting PR Newswire
05.11.25 - PR Newswire
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference PR Newswire
29.10.25 - PR Newswire
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results PR Newswire
22.10.25 - PR Newswire
Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025
Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 PR Newswire

Newssuche

Videos

newspaper
10:40 Uhr +50,48%
Technical Trading: DAX Long Chance
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »